Loading companies…
Loading companies…
Switzerland · Biotech · Enterprise software
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $152M | Droia — Role not disclosedEQT Life Sciences — Role not disclosedGoldman Sachs Alternatives — Role not disclosedKalehua Capital — Role not disclosedMedicxi — Role not disclosedOmega Funds — Role not disclosedPerceptive Advisors — Role not disclosedTCGX — Role not disclosed |